LYRA (LYRA THERAPEUTICS INC)
Insider Trading Activity
Every open-market purchase and sale reported by LYRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-08 | Maria Palasis | President & CEO | Sell | — | — |
| 2026-01-08 | Jason Cavalier | Chief Financial Officer | Sell | — | — |
| 2025-11-13 | Perceptive LS (A), LLC | 10%+ Owner | Sell | — | — |
| 2025-11-10 | Perceptive LS (A), LLC | 10%+ Owner | Sell | — | — |
| 2025-10-08 | Maria Palasis | President & CEO | — | — | — |
| 2025-10-03 | Maria Palasis | President & CEO | A | — | — |
| 2025-07-14 | Maria Palasis | President & CEO | Sell | — | — |
| 2025-07-14 | Jason Cavalier | Chief Financial Officer | Sell | — | — |
| 2025-05-16 | W Bradford Smith | Director | A | — | — |
| 2025-05-16 | C ANN MERRIFIELD | Director | A | — | — |
| 2025-05-16 | nancy lynn MD snyderman | Director | A | — | — |
| 2025-05-16 | JAMES R TOBIN | Director | A | — | — |
| 2025-01-10 | Jason Cavalier | Chief Financial Officer | A | — | — |
| 2025-01-10 | Maria Palasis | President & CEO | A | — | — |
| 2024-12-11 | Maria Palasis | President & CEO | A | — | — |
| 2024-12-11 | Harlan Waksal | Executive Chair | A | — | — |
| 2024-10-18 | Maria Palasis | President & CEO | A | — | — |
| 2024-10-18 | Jason Cavalier | Chief Financial Officer | A | — | — |
| 2024-06-14 | MICHAEL SETH ALTMAN | Director | A | — | — |
| 2024-06-14 | JAMES R TOBIN | Director | A | — | — |
| 2024-06-14 | Konstantin Poukalov | Director | A | — | — |
| 2024-06-14 | C ANN MERRIFIELD | Director | A | — | — |
| 2024-06-14 | nancy lynn MD snyderman | Director | A | — | — |
| 2024-06-14 | W Bradford Smith | Director | A | — | — |
| 2024-03-20 | Harlan Waksal | Executive Chair | A | — | — |
| 2024-03-20 | Maria Palasis | President & CEO | A | — | — |
| 2024-02-01 | Richard Nieman | Chief Medical Officer | A | — | — |
| 2024-02-01 | John E Bishop | Chief Technology Officer | A | — | — |
| 2024-02-01 | Jason Cavalier | Chief Financial Officer | A | — | — |
| 2023-11-13 | Harlan Waksal | Executive Chair | Buy | — | — |
| 2023-07-12 | Maria Palasis | President & CEO | A | — | — |
| 2023-07-05 | Konstantin Poukalov | Director | A | — | — |
| 2023-07-05 | nancy lynn MD snyderman | Director | A | — | — |
| 2023-07-05 | EDWARD T ANDERSON | Director | A | — | — |
| 2023-07-05 | JAMES R TOBIN | Director | A | — | — |
| 2023-07-05 | W Bradford Smith | Director | A | — | — |
| 2023-07-05 | C ANN MERRIFIELD | Director | A | — | — |
| 2023-07-05 | MICHAEL SETH ALTMAN | Director | A | — | — |
| 2023-06-26 | Maria Palasis | President & CEO | A | — | — |
| 2023-06-02 | PERCEPTIVE ADVISORS LLC | Director | Buy | — | — |
| 2023-06-02 | North Bridge Venture Management V, L.P. | 10%+ Owner | Buy | — | — |
| 2023-06-02 | EDWARD T ANDERSON | Director | Buy | — | — |
| 2023-02-28 | John E Bishop | Chief Technology Officer | A | — | — |
| 2023-02-02 | Harlan Waksal | Executive Chair | A | — | — |
| 2023-02-02 | Jason Cavalier | Chief Financial Officer | A | — | — |
| 2023-02-02 | Maria Palasis | President & CEO | A | — | — |
| 2023-02-02 | Richard Nieman | Chief Medical Officer | A | — | — |
| 2023-02-02 | Corinne Noyes | See Remarks | A | — | — |
| 2023-02-02 | Robert E. Richard | SVP, Technical Operations | A | — | — |
| 2022-07-12 | Richard Nieman | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President & CEO | 1,096,733 | — |
| — | Chief Financial Officer | 518,547 | — |
| — | 10%+ Owner | 50,435 | — |
| — | Director | 47,556 | — |
| — | Director | 26,182 | — |
| — | 10%+ Owner | 25,769 | — |
| — | Director | 25,769 | — |
| — | 10%+ Owner | 21,245 | — |
| — | 10%+ Owner | 18,188 | — |
| — | 10%+ Owner | 15,572 | — |
| — | 10%+ Owner | 14,026 | — |
| — | Executive Chair | 10,739 | — |
| — | 10%+ Owner | 6,340 | — |
| — | 10%+ Owner | 3,100 | — |
| — | 10%+ Owner | 1,168 | — |
| — | Director | 1,101 | — |
| — | See Remarks | 733 | — |
| — | SVP, Technical Operations | 600 | — |
| — | Director | 303 | — |
| — | Director | 227 | — |
| — | Director | 20 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LYRA quote page; the site-wide leaderboard is on the insider transactions hub.